Liposome-anchored vascular endothelial growth factor aptamers

Bioconjugate Chemistry

Volumn 9, Issue 5, 1998, Pages 573-582

  Willis, Michael C ^a   Collins, Brian ^b   Zhang, Tong ^b   Green, Louis S ^a   Sebesta, David P ^a   Bell, Carol ^a   Kellogg, Elizabeth ^a   Gill, Stanley C ^a   Magallanez, Anna ^a   Knauer, Susan ^a   Bendele, Ray A ^a   Gill, Parkash S ^b   Janjić, Nebojša ^a  

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ENGINEERING; CELL PROLIFERATION; ENDOTHELIAL CELLS;

ANCHORINGS; APTAMERS; BI-LAYER; DRUG CANDIDATES; FUNCTIONAL PROPERTIES; HIGH AFFINITY BINDING; PROPERTY; RESIDENCE TIME; SYNTHESISED; VASCULAR ENDOTHELIAL GROWTH FACTOR;

NUCLEIC ACIDS;

EID: 0032170107     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc980002x     Document Type: Article

References (43)

1. Tuerk, C., and Gold, L. (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510.
2. Ellington, A., and Szostak, J. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822.
3. Gold, L. (1995) Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270, 13581-13584.
4. Gold, L., Polisky, B., Uhlenbeck, O. C., and Yarus, M. (1995) Diversity of oligonucleotide functions. Annu. Rev. Biochem. 64, 763-797.
5. Lin, Y., Qiu, Q., Gill, S. C., and Jayasena, S. (1994) Modified RNA sequence pools for in vitro selection. Nucleic Acids Res. 22, 5229-5234.
6. Latham, J. A., Johnson, R., and Toole, J. J. (1994) The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2′-deoxyuridine. Nucleic Acids Res. 22, 2817-2822.
7. Jellinek, D., Green, L. S., Bell, C., Lynott, C. K., Gill, N., Vargeese, C., Kirschenheuter, G., McGee, D. P. C., Abesinghe, P., Pieken, W. A., Shapiro, R., Rifkin, D. B., Moscatelli, D., and Janjic, N. (1995) Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34, 11363-11372.
8. Pagratis, N. C., Bell, C., Chang, Y.-F., Jennings, S., Fitzwater, T., Jellinek, D., and Dang, C. (1997) Potent 2′-amino- and 2′-fluoro-2′-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat. Biotechnol. 15, 68-73.
9. Green, L. S., Jellinek, D., Bell, C., Beebe, L. A., Feistner, B. D., Gill, S. C., Jucker, F. M., and Janjić, N. (1995) Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem. Biol. 2, 683-695.
10. Folkman, J. (1995) Angiogenesis in cancer, vascular and other diesease. Nat. Med. 1, 27-31.
11. Conn, G., Soderman, D. D., Schaeffer, M.-T., Wile, M., Hatcher, V. B., and Thomas, K. A. (1990) Purification of a glycoprotcin vascular endothelial cell mitogen from a rat glioma-derived cell line (GS-9L). Proc. Natl. Acad. Sci. U.S.A. 87, 1323-1327.
12. Gospodarowicz, D., Abraham, J. A., and Schilling, J. (1989) Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. Proc. Natl. Acad. Sci. U.S.A. 86, 7311-7315.
13. Ferrara, N., and Henzel, W. J. (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858.
14. Dvorak, H. F., Orenstein, N. S., Carvalho, A. C., Churchill, W. H., Dvorak, A. M., Galli, S. J., Feder, J., Bitzer, A. M., Rypysc, J., and Giovinco, P. (1979) Induction of fibrin-gel investment: an early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122, 166-174.
15. Senger, D. R., Galli, S. J., Dvorak, A. M., Peruzzi, C. A., Harvey, V. S., and Dvorak, H. F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
16. Senger, D. R., Peruzzi, C. A., Feder, J., and Dvorak, H. F. (1986) A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res. 46, 5629-5632.
17. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039.
18. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845.
19. Levy, A. P., Levy, N. S., and Goldberg, M. A. (1996) Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271, 2746-2753.
20. Thomas, K. A. (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271, 603-606.
21. Brown, L. F., Detmar, M., Claffey, K., Nagy, J. A., Feng, D., Dvorak, A. M., and Dvorak, H. F. (1997) Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. In Regulation of Angiogenesis (I. D. Goldberg and E. M. Rosen, Eds.) pp 233-269, Birkhauser, Basel, Switzerland.
22. Houck, K. A., Ferrara, N., Winer, J., Cachianes, G., Li, B., and Leung, D. W. (1991) The vascular endothelial growth factor family: identificaiton of a fourth species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5, 1806-1814.
23. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. (1991) The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266, 11947-11954.
24. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N. P. H., Risau, W., and Ullrich, A. (1993) High affinity vascular endothelial growth factor binding and developmental expression suggest flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846,
25. Terman, B. I., Carrion, M. E., Kovacs, E., Rasmussen, B. A., Eddy, R. L., and Shows, T. B. (1991) Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6, 519-524.
26. de Vries, C., Escobendo, J. A., Ueno, H., Houck, K., Ferrara, N., and Williams, L. T. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991.
27. Mustonen, T., and Alitalo, K. (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J. Cell Biol. 129, 895-898.
28. Gill, S. C., Weitzel, S. E., and von Hippel, P. H. (1991) E. coli Sigma70 and NusA proteins. Binding interactions with core RNA polymerase in solution and within the transcription complex. J. Mol. Biol. 220, 307-324.
29. Miles, A. A., and Miles, E. M. (1952) Vascular reactions to histamine, histamine-liberator, and leukotaxine in the skin of guinea pigs. J. Physiol. (London) 118, 228-257.
30. Hope, M. J., Wong, K. F., and Cullis, P. R. (1989) Freeze-fracture of lipids and model membrane systems. J. Electron Microsc. Tech. 13, 277-287.
31. Jain, M. K., and Wagner, R. C. (1980) Introduction to Biological Membranes, p 63, Wiley, New York.
32. Auerbach, R., Auerbach, W., and Polakowski, I. (1991) Assays for angiogenesis: a review. Pharmacol. Ther. 51, 1-11.
33. Hicke, B. J., Watson, S. R., Koenig, A., Lynott, C. K., Bargatze, R. F., Chang, Y.-F., Ringquist, S., Moon-McDermott, L., Jennings, S., Fitzwater, T., Han, H.-L., Varki, N., Albinana, I., Willis, M. C., Varki, A., and Parma, D. (1996) DNA aptamers block L-selectin function in vivo. Inhibition of human lymphocyte trafficking in SCID mice. J. Clin. Invest. 98, 2688-2692.
34. Letsinger, R. L., Zhang, G., Sun, D. K., Ikeuchi, T., and Sarin, P. S. (1989) Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. Proc. Natl. Acad. Sci. U.S.A. 86, 6553-6556.
35. Saison-Behmoaras, T., Tocqué, B., Rey, I., Chassignol, M., Thuong, N. T., and Hélène, C. (1991) Short modified antisense oligonucleotides directed against Ha-ras point mutations induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J. 10, 1111-1118.
36. Shea, R. G., Marsters, J. C., and Bischofberger, N. (1990) Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates. Nucleic Acids Res. 18, 3777-3783.
37. MacKellar, C., Graham, D., Will, D. W., Burgess, S., and Brown, T. (1992) Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. Nucleic Acids Res. 20, 3411-3417.
38. de Smidt, P. C., Le Doan, T., de Falco, S., and van Berkel, T. J. C. (1991) Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and midifies the tissue distribution. Nucleic Acids Res. 19, 4695-4700.
39. Zalipsky, S., Puntambekar, B., Boulikas, P., Engbers, C. M., and Woodle, M. C. (1995) Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR. Bioconjugate Chem. 6, 705-708.
40. DeFrees, S. A., Phillips, L., Guo, L., and Zalipsky, S. (1996) Sialyl Lewis x liposomes as a multivalent ligand and inhibitor of E-selectin mediated cellular adhesion. J. Am. Chem. Soc. 118, 6101-6104.
41. Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., and Zalipsky, S. (1995) A new strategy for attachment to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237, 99-108.
42. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W.-L., Carter, P., Benz, C. C., and Papahadjopoulos, D. (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36, 66-75.
43. Spragg, D. D., Alford, D. R., Greferath, R., Larsen, C. E., Lee, K-D., Gurtner, G. C., Cybulsky, M. I., Tosi, P. F., Nicolau, C., and Gimbrone, M. A. (1997) Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc. Natl. Acad. Sci. U.S.A. 94, 8795-8800.